Similarly, for NSCLC patients with BRAFV600 mutations, there have been reports of sustained benefits from immunotherapy, but whether their efficacy is enhanced when used in combination with BRAF and/or MEK inhibitors (including FDA-approved drugs vemurafenib, dabrafenib, and trametinib), similar to that against melanoma, might also require real-world data, as controlled studies may not be feasible. Here, MAP2K7 is linked to non-small cell lung carcinoma.